ArticleBlood2022

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.

Swetha Kambhampati Thiruvengadam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.